Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma

Journal of the National Cancer Institute

Volumn 97, Issue 6, 2005, Pages 457-460

  Chan, Andrew T ^a,b   Tranah, Gregory J ^d   Giovannucci, Edward L ^c,d   Hunter, David J ^b,c,d   Fuchs, Charles S ^b,c,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER HARVARD CANCER CENTER   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A6; UNCLASSIFIED DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; UGT1A6 PROTEIN, HUMAN;

ARTICLE; CANCER RISK; CASE CONTROL STUDY; CHEMOPROPHYLAXIS; COLONOSCOPY; COLORECTAL ADENOMA; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK REDUCTION; STATISTICAL SIGNIFICANCE; TABLET FORMULATION; WILD TYPE; ADENOMA; AGED; COLORECTAL TUMOR; ENZYMOLOGY; EPIDEMIOLOGY; GENETIC POLYMORPHISM; GENETICS; INCIDENCE; MIDDLE AGED; RISK; RISK ASSESSMENT; UNITED STATES;

ADENOMA; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CASE-CONTROL STUDIES; COLONOSCOPY; COLORECTAL NEOPLASMS; CONFIDENCE INTERVALS; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; INCIDENCE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RISK ASSESSMENT; UNITED STATES;

EID: 14944371215     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/dji066     Document Type: Article

References (29)

1. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
2. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90.
3. Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003;125:328-36.
4. Chan AT, Giovannucci EL, Schernhammer ES, Colditz GC, Hunter DJ, Willett WC, et al. A prospective study of aspirin use and the risk of colorectal adenoma. Ann Intern Med 2004;140:157-66.
5. Chan AT. Aspirin, non-steroidal anti-inflammatory drugs, and colorectal neoplasia: future challenges in chemoprevention. Cancer Causes Control 2003;14:413-8.
6. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
7. Tangrea JA, Albert PS, Lanza E, Woodson K, Corle D, Hasson M, et al. Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States). Cancer Causes Control 2003;14:403-11.
8. Hutt AJ, Caldwell J, Smith RL. The metabolism of aspirin in man: a population study. Xenobiotica 1986;16:239-49.
9. Ciotti M, Marrone A, Potter C, Owens IS. Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications. Pharmacogenetics 1997;7:485-95.
10. Bigler J, Whitton J, Lampe JW, Fosdick L, Bostick RM, Potter JD. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res 2001;61:3566-9.
11. Belanger CF, Hennekens CH, Rosner B, Speizer FE. The nurses' health study. Am J Nurs 1978;78:1039-40.
12. Platz EA, Hankinson SE, Rifai N, Colditz GA, Speizer FE, Giovannucci E. Glycosylated hemoglobin and risk of colorectal cancer and adenoma (United States). Cancer Causes Control 1999;10:379-86.
13. Chan AT, Tranah GJ, Giovannucci EL, Hunter DJ, Fuchs CS. A prospective study of genetic polymorphisms in the cytochrome P450 2C9 enzyme and the risk of distal colorectal adenoma. Clin Gastro Hepatol 2004;2:704-12.
14. Baron JA, Cole B.F., Mott, L.A. et al. Aspirin chemoprevention of colorectal adenomas. Proc Am Assoc Cancer Res 2002:669.
15. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609-14.
16. Gatto NM, Frucht H, Sundararajan V, Jacobson JS, Grann VR, Neugut AI. Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. J Natl Cancer Inst 2003;95:230-6.
17. Giovannucci E, Colditz GA, Stampfer MJ, Hunter D, Rosner BA, Willett WC, et al. A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in U.S. women. J Natl Cancer Inst 1994;86: 192-9.
18. Lampe JW, Bigler J, Horner NK, Potter JD. UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics 1999;9:341-9.
19. Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001;119: 39S-63S.
20. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8.
21. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994;265:956-9.
22. He TC, Chan TA, Vogelstein B, Kinzler KW. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999;99:335-45.
23. Shureiqi I, Chen D, Lotan R, Yang P, Newman RA, Fischer SM, et al. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res 2000;60:6846-50.
24. Willett WC, Sampson L, Stampfer MJ, Rosner B, Bain C, Witschi J, et al. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol 1985;122:51-65.
25. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994;121:241-6.
26. Rimm E, Stampfer M, Colditz G, Litin L, Willett W. Validity of self-reported waist and hip circumferences in men and women. Epidemiology 1990;1:466-73.
27. Wolf AM, Hunter DJ, Colditz GA, Manson JE, Stampfer MJ, Corsano KA, et al. Reproducibility and validity of a self-administered physical activity questionnaire. Int J Epidemiol 1994;23:991-9.
28. Breslow NE, Day NE. Statistical methods in cancer research. Vol. 2. The design and analysis of cohort studies.. IARC Sci Publ 1987:1-406.
29. Imperiale TF. Aspirin and the prevention of colorectal cancer. N Engl J Med 2003;348: 879-80.